Clinical Trial Update: An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ivabradine for exercise capacity in heart transplant recipients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Drugs mentioned

• IVABRADINE

Snippet

Sponsor: Amgen | Conditions: Heart Transplantation, Elevated Resting Heart Rate | Phase 3 | Status: WITHDRAWN